spacer
home > ebr > winter 2002 > overview of the biotechnology industry in finland
PUBLICATIONS
European Biopharmaceutical Review

Overview of the Biotechnology Industry in Finland

Finland's knowledge-based growth strategy provides strong support for research and development, with investments in R&D having risen steadily since the early 1980s. In this respect, the most important recent event was the decision taken by the Government in 1996 to allocate funds from the privatisation of state-owned companies to fund science and technology. The goal was to increase the national R&D input to 2.9 per cent of GDP by 1999. Owing to rapidly increasing investment by the private sector, this level was achieved a year ahead of schedule. Today the figure, which is made up of public funding and the input from industry, has risen to 3.6 per cent. This puts Finland second in the world for R&D spending per capita. Of the total R&D investment, 29 per cent is funded by Government and 71 per cent by the private sector.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sirkka Aura, CEO of Invest in Finland Sirkka Aura is Chief Executive Officer of Invest in Finland. Her particular expertise lies in the banking and financial sectors and is complemented by industry knowledge from a wide range of fields.
Prior to joining the IFB, Sirkka spent 12 years with Leonia Bank Oy in various posts including two years as Vice-President of their New York branch and several years as Manager of the bank's foreign corporate customers. She has an MSc from the Helsinki School of Economics and Business Administration.

spacer
Sirkka Aura
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

International biomed specialist appoints WHP to deliver key expansion project

New state of the art cleanroom facilities will enable a leading international gene and cell therapy company to expand its bioprocessing operations and manufacturing capabilities.
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement